Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2021 | Adjuvant therapy for high-risk melanoma

Jason J. Luke, MD, FACP, University of Pittsburgh, Pittsburgh, PA, discusses adjuvant therapy for high-risk melanoma. Approved treatments include PD-1 and BRAF inhibitors for stage 3 melanoma. Recent research has shown that stage 2 patients are at a similar level of risk of 5- and 10-year survival to stage 3 patients. KEYNOTE-716 has led the way for PD-1, BRAF, and MEK inhibitors being used in adjuvant therapy for patients with stage 2 melanoma. Dr Luke recommends that future research focuses on how to refine and increase the benefit of adjuvant treatment for these patient populations. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.

Disclosures

Dr Luke reports DSMB: Abbvie, Immutep. Scientific Advisory Board: (no stock) 7 Hills, Fstar, Inzen, RefleXion, Xilio (stock) Actym, Alphamab Oncology, Arch Oncology, Kanaph, Mavu, Onc.AI, Pyxis, Tempest.

Dr Luke reports consultancy with compensation: Abbvie, Alnylam, Avillion, Bayer, Bristol-Myers Squibb, Checkmate, Codiak, Crown, Day One, Eisai, EMD Serono, Flame, Genentech, Gilead, HotSpot, Kadmon, KSQ, Janssen, Ikena, Immunocore, Incyte, Macrogenics, Merck, Mersana, Nektar, Novartis, Pfizer, Regeneron, Ribon, Rubius, Silicon, Synlogic, Synthekine, TRex, Werewolf, Xencor.

Dr Luke reports research support: (all to institution for clinical trials unless noted) AbbVie, Agios (IIT), Astellas, Astrazeneca, Bristol-Myers Squibb (IIT & industry), Corvus, Day One, EMD Serono, Fstar, Genmab, Ikena, Immatics, Incyte, Kadmon, KAHR, Macrogenics, Merck, Moderna, Nektar, Next Cure, Numab, Pfizer (IIT & industry) Replimmune, Rubius, Scholar Rock, Synlogic, Takeda, Trishula, Tizona, Xencor/

Dr Luke reports patents: (both provisional) Serial #15/612,657 (Cancer Immunotherapy), PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)